News | April 26, 2023
Siegfried breaks ground on new R&D center for drug substances in Switzerland
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
This plant adds around 60,000 MT of capacity, scaling Jubilant Ingrevia Limited’s overall annual Acetic Anhydride capacity to 210,000 MT
The Theme of the event was 'Building One Health Together – Improving Health Equity'
The meeting provides recommendations to the G20 and its Member States and international partners on the establishment of a R&D and manufacturing network for diagnostics
Affordability is key to providing accessible healthcare for Bharat.
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
The new team members, Solenn Percelay and Noémie Spinelli, will support the organization’s commitment to excellence in humanized mouse model care and use
The introduction of Octasa 1600 mg to the Canadian market is expected to increase the options for UC patients managed with mesalazine.
Government hospitals like AIIMS, KGMC & many more as per day OPD patients are 18-25 thousand
Subscribe To Our Newsletter & Stay Updated
